• Grail published a medical research presentation evaluating targeted ctDNA methylation profiling for liver and biliary tract cancers.
• The blood test detected cancer signals in 86-95% of samples from 657 patients across three phase 3 trials.
• A research-grade classifier identified 99.2% of biliary tract cancers as adenocarcinoma-like; HCC classification accuracy reached 77.4-81.9%.
• Confirmed HCC samples classified as adenocarcinoma-like had lower tumor methylation fractions, highlighting a need for further classifier refinement and validation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief on November 07, 2026, and is solely responsible for the information contained therein.